Please login to the form below

Pfizer/BioNTech

This page shows the latest Pfizer/BioNTech news and features for those working in and with pharma, biotech and healthcare.

CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval

The potential approval of CVnCoV comes months after the emergency authorisations of other mRNA-based vaccines, namely Moderna and Pfizer/BioNTech’s respective jabs.

Latest news

UK trial evaluating mixed-vaccine regimens includes two more jabs

When the study first launched, the Department of Health and Social Care (DHSC) said that study participants could receive AstraZeneca (AZ)/Oxford University’s vaccine for their first dose and ... BioNTech’s vaccine for the second, or vice versa.
J&J delays EU COVID-19 vaccine rollout following pause in the US

clot cases had been reported among people who have received the Pfizer/BioNTech or Moderna vaccines, both of which are being widely used in the US.
Sanofi pays $160m upfront to acquire Tidal Therapeutics

This includes Pfizer/BioNTech and Moderna, whose mRNA-based vaccines are designed to teach the body’s own cells how to create a protein, or part of the protein, that triggers ... BioNTech also has a number of mRNA-based candidates in development for
Moderna vaccine given to first UK recipient in Wales

The Moderna vaccine will be administered in two doses, given between four and 12 weeks apart, in the same way as the Pfizer-BioNTech and Oxford-AstraZeneca vaccines that are already ... The Moderna vaccine can also be shipped at -20C, which is closer to
EU considers blocking COVID-19 vaccine exports to the UK

According to The Guardian, most of the vaccines exported from the EU to the UK are the Pfizer/BioNTech vaccine that is manufactured at the company’s European production sites. ... The EU has faced a number of problems during its COVID-19 vaccine

More from news
Approximately 46 fully matching, plus 98 partially matching documents found.

Latest Intelligence

Rare genetic diseases – what’s in store for 2021?

In the UK, the looming Brexit sparked new models of regulatory approval and fast-track opportunities, as recently observed in the rapid approval of Pfizer’s COVID-19 vaccine. ... So far the Pfizer/BioNTech, Moderna and AstraZeneca/Oxford University
Working together against COVID-19

Beyond the connection between HCPs and pharma or NGOs, it is encouraging to see collaborations such as Clover and GSK evaluating a vaccine candidate and Pfizer and Biontech doing the same. ... A number of top pharma companies are included in the newly

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

What does the COVID-19 vaccine mean for the future of R&D?

Both the Oxford/AstraZeneca and Pfizer/BioNTech vaccines were developed using platform technologies which didn’t exist 20 years ago, allowing these vaccines to be developed much faster.
The UK has approved the first vaccine for COVID-19. What now?

The authorisation of Pfizer/BioNtech's mRNA vaccine by the MHRA is great news, but no-one has ever tried to roll out a vaccine as rapidly as this one, so
Mistrust in medical research: a patient perspective

Health Products Regulatory Agency’s speedy approval of the Pfizer-BioNTech COVID-19 vaccine in the UK. ... A good example is a recent incident in the UK that made headline news, where two NHS workers who were among the first to receive the
Is the world ready for a COVID-19 vaccine?

At the beginning of November, Pfizer and BioNTech announced that their vaccine candidate was more than 90% effective at preventing COVID-19 infection. ... At the beginning of November, Pfizer and BioNTech announced that their vaccine candidate was more
Hanover Communications

At the beginning of November, Pfizer and BioNTech announced that their vaccine candidate was more than 90% effective at preventing COVID-19 infection.

More from PMHub
Approximately 0 fully matching, plus 6 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Senior Account Director & Associate Director - Healthcare Ad...: Highly Competitive Salary, Bonus &Benefits

Home Working Medical Copy Writer & Senior Medical Copy Write...: Highly Competitive Salary, Bonus &Benefits

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Client Services Director – London or Home Based – Medical Commun...: Highly Competitive Salary, Bonus &Benefits

Medical Writer, Senior Medical Writer, Principal Medical Writer,...: Highly Competitive Salary, Bonus &Benefits

Editor & Senior Editor - Medical Communications - Home Based: Highly Competitive Salary, Bonus &Benefits

Senior Content Editor - Biotechnology: Salary TBC

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Account Management: Competitive Salary Offered

PMHub

Add my company

Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story: How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?: The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19: The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...